Trial Profile
A phase 1 pharmacokinetic and safety study of VNRX-5133 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2018
Price :
$35
*
At a glance
- Drugs Cefepime/taniborbactam (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; Pharmacokinetics
- 08 Nov 2018 New trial record
- 07 Oct 2018 Results assessing pharmacokinetic and safety of VNRX-5133 in healthy subjects, presented at the IDWeek 2018.